Systems and methods that facilitate the automatic (or substantially automatic) preparation of a sample of a product containing molecules for analysis and automatic (or substantially automatic) performance of an assay of that sample. Thus, the preparation and analysis can be performed substantially in-real time, or, in other words, much more quickly than presently allowed by conventional systems and methods.
An apparatus is for nondestructive detection of one or more transparent or reflective objects in a vessel that is at least partially filled with a fluid. The apparatus comprises an imager, a memory and a processor. The imager is configured to acquire data that represent light reflected from a plurality of spatial locations in the vessel as a function of time. The memory is operably coupled to the imager and configured to store the data. The processor is operably coupled to the memory and configured to detect the objects based on the data by: (i) identifying a respective maximum amount of reflected light for each location in the plurality of locations, and (ii) determining a presence or absence of the objects in the vessel based on the number of spatial locations whose respective maximum amount of reflected light exceeds a predetermined value.
An apparatus for injection of a therapeutic product, the apparatus comprising: an autoinjector; and a single-use cassette for use with the injector, the cassette comprising: a housing; a sleeve disposed in the housing and movable between first and second positions; a syringe disposed in the sleeve; and a shield remover extending through an opening in a proximal end of the housing for removing a needle shield from the syringe.
Disclosed are a wearable drug delivery device and related method. The delivery device may comprise an outer housing; a drug storage container positioned at least partially within the outer housing; and an insertion mechanism positioned at least partially within the outer housing and including: an insertion mechanism housing, a rotational biasing member configured to rotate the insertion mechanism housing, a delivery member moveable between a first position and a second position, a hub configured to: (i) facilitate a fluid connection between the delivery member and drug storage container such that a fluid flow path passes through at least a portion of the hub during operation of the device, and (ii) mechanically interact with the insertion mechanism housing such that initial rotation of the insertion mechanism housing with respect to the hub causes the delivery member to move axially from the first position to the second position.
The present invention provides combination therapy that includes an KRASG12C inhibitor, such as (see Formula), or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
The present invention relates to RNAi constructs for reducing expression of the ASGRI gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
8.
N-ACETYLATED AND NON-ACETYLATED DIPEPTIDES CONTAINING ARGININE TO REDUCE THE VISCOSITY OF VISCOUS COMPOSITIONS OF THERAPEUTIC POLYPEPTIDES
Provided herein are excipients capable of effectively reducing the viscosity of polypeptide (e.g., therapeutic polypeptide) formulations. The viscosity reducing excipients are dipeptides containing arginine at the carboxy terminus and N-acetylated serine or N-acetylated proline at the N-terminus. Glutamine-arginine is also disclosed as a viscosity-reducing dipeptide. Among the disclosed methods, methods of reducing the viscosities of such formulations are also provided.
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
9.
CB1 RECEPTOR ANTIGEN-BINDING PROTEINS AND USES THEREOF
This disclosure relates to CB1 receptor antigen-binding proteins, e.g. antibodies and methods of using the CB1 receptor antibodies. The CB1 receptor antibodies may comprise an antagonistic antibody to CB1 receptors and may be used to treat various health conditions. The health conditions can comprise obesity or diabetes or any disease that benefits from antagonism of the CB1 receptor.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
10.
MAGNETIC ASSISTED SEPARATION APPARATUSES AND RELATED METHODS
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
12.
METHODS FOR MODULATING MONOCLONAL ANTIBODY CHARGE VARIANTS
The present invention relates to methods of modulating the charge variant profile of a recombinantly produced monoclonal antibody by altering bioreactor media hold durations. Methods of increasing product yield and titer by manipulating media hold durations are also described.
The disclosure provides methods for analyzing two or more different therapeutic proteins co-formulated in a sample mixture. The methods involve intact mass analysis, peptide mapping, and a multi-attribute method (MAM) to detect, quantify, and monitor critical quality attributes (CQAs) of co-formulated therapeutic proteins, such as monoclonal antibodies.
Disclosed herein are expression cassettes, expression vectors, dual vector systems, and mammalian host cells, including but not limited to Chinese hamster ovary (CHO) cells, comprising the foregoing, for the expression of certain antibody modalities, wherein each expression vector employs a promoter set optimized for the antibody modality. Also disclosed herein are methods of producing certain antibody modalities using these mammalian host cells.
Disclosed herein are expression systems for producing multi-specific antibodies having only one Fab or having two Fabs that are identical, host cells comprising such expression systems, including but not limited to Chinese hamster ovary (CHO) cells, and methods for producing multi- specific antibodies utilizing such expression systems.
A computer-implemented method for generating one or more modified amino acid sequences comprises obtaining, via one or more processors, one or more candidate amino acid sequences and characteristic data associated with the one or more candidate amino acid sequences; classifying, via the one or more processors, the one or more candidate amino acid sequences into a first set of high-viscous amino acid sequences and a second set of low-viscous amino acid sequences using a predictive model, the classifying comprising: calculating one or more viscosity predictions based on the one or more candidate amino acid sequences and the obtained characteristic data; and determining the first set of high-viscous amino acid sequences and the second set of low-viscous amino acid sequences based on the one or more viscosity predictions and a predetermined viscosity threshold, wherein the first set of high-viscous amino acid sequences comprises at least one candidate amino acid sequence; and generating, via the one or more processors, the one or more modified amino acid sequences based on the first set of high-viscous amino acid sequences using a generative model, wherein at least one of the one or more modified amino acid sequences has a viscosity prediction lower than the predetermined viscosity threshold.
The present disclosure, relates, in general, to methods of treating chronic obstructive pulmonary disease (COPD) using an antibody specific for thymic stromal lymphopoietin (TSLP).
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
18.
INTEGRATED BUBBLE TRAP DEVICE AND CLAMP FOR WORKING HEART APPARATUS
An integrated bubble trap device for a working heart system includes a body having an internal cavity configured to be partially filled with a liquid, an inlet configured to be in fluid communication with a liquid reservoir, an outlet configured to connect to a left atrium of an excised heart of a test specimen, and a syringe port configured to connect the internal cavity of the body with a syringe. An aperture at the bottom of the body is configured to connect to a pressure sensor. The integrated bubble trap device may further include a catheter extension configured to connect the liquid reservoir to the inlet adapter of the integrated bubble trap device and an adjustable clamp to hold the liquid reservoir in a position. In a method of use, the integrated bubble trap device removes bubbles from a perfusion buffer.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
G06F 119/02 - Reliability analysis or reliability optimisationFailure analysis, e.g. worst case scenario performance, failure mode and effects analysis [FMEA]
21.
STABILIZING HOMODIMER MUTATIONS FOR TWO CELL HETERODIMER PRODUCTION
The present invention relates to methods of producing homodimers comprising mutations in the CH3 domains. Said mutations increase the stability of the homodimer, resulting in increased homodimer yield. Said homodimers are separately expressed and purified, and reassembled into heterodimers.
A packaging for drug administration comprises a carton having a storage configuration and an assembled configuration. The carton comprises a bottom box having a first bottom wall, a first sidewall, a second sidewall, a first back wall, and a first front wall when the carton is in the assembled configuration, and a lid coupled to the bottom box and movable between an open position and a closed position. The packaging also comprises a tray configured to be disposed within the bottom box of the carton. The tray also has a storage configuration and an assembled configuration. In the assembled configuration, the tray comprises a plurality of cavities dimensioned to house one or more drug delivery components.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
23.
RADIOLABELED COMPOUNDS FOR THE DETECTION OF STEAP1
The present invention relates to anti-STEAP1 constructs for the use of detecting STEAP1 in a subject. The invention further relates to anti-STEAP1 (Fab')2 fragments that are radiolabeled. Said constructs are useful for imaging STEAP1 expression, for example, in a positron emission tomography scan.
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
24.
OPTIMIZATION OF MOTION PROFILE USING COMPUTATIONAL FLUID DYNAMICS
G01N 21/90 - Investigating the presence of flaws, defects or contamination in a container or its contents
G06F 30/28 - Design optimisation, verification or simulation using fluid dynamics, e.g. using Navier-Stokes equations or computational fluid dynamics [CFD]
System (100) and method of foil packaging components of a drug delivery device (110), e.g. autoinjector, pen injector, involving introducing first and second sheets of foil (101, 103) into a welding assembly with welding bars (106a, 106b), welding the sheets of foil (101, 103) together to form a first weld (112), providing a pen injector component (110) between the sheets of foil (101, 103) above the first welded, moving the sheets of foil (101, 103) downwards, and welding the first and second sheets of foil (101, 103) together to form a second weld (112) above the pen injector component (110). This can provide a foil packaging (120) with the pen injector components (110). Also disclosed is a system (200) and method for unloading or unpacking the foil packaged components of drug delivery device (110) which involves pushing a rod (210) between the welds in the foil packaging (120).
G01B 11/24 - Measuring arrangements characterised by the use of optical techniques for measuring contours or curvatures
G01B 11/25 - Measuring arrangements characterised by the use of optical techniques for measuring contours or curvatures by projecting a pattern, e.g. moiré fringes, on the object
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
36.
MAJOR HISTOCOMPATIBILITY COMPLEX (MHC)-ASSOCIATED PEPTIDE PROTEOMICS (MAPPS) ASSAY FOR IMMUNOGENICITY RISK ASSESSMENT OF BIOTHERAPEUTIC ATTRIBUTES
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
39.
DRUG DELIVERY DEVICE HAVING A REAR CAP FOR INCREASED DROP ROBUSTNESS
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
40.
MACHINE LEARNING-BASED EVALUATION OF DEVICE LABEL PLACEMENT
G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61B 50/30 - Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
G01N 30/88 - Integrated analysis systems specially adapted therefor, not covered by a single one of groups
G01N 30/96 - Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography using ion-exchange
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
47.
MACHINE LEARNING (ML)-BASED SYSTEMS AND METHODS FOR PREDICTING DISEASE
G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
49.
METHODS FOR DETECTING A PROTEIN IN A SAMPLE IN A FLUIDIC DEVICE USING MASS SPECTROMETRY
The disclosure provides for methods of detecting and analyzing proteins using mass spectrometry analysis, such as matrix assisted laser desorption ionization mass spectrometry (MALDI-MS) on protein directly within a fluidic device, or reversed phase liquid chromatographic mass spectrometry (rpLC-MS) on protein outside of the fluidic device.
B65B 57/08 - Automatic control, checking, warning or safety devices responsive to absence, presence, abnormal feed, or misplacement of binding or wrapping material, containers, or packages and operating to stop, or to control the speed of, the machine as a whole
B65B 57/16 - Automatic control, checking, warning or safety devices responsive to absence, presence, abnormal feed, or misplacement of articles or materials to be packaged and operating to stop, or to control the speed of, the machine as a whole
B65B 57/18 - Automatic control, checking, warning or safety devices causing operation of audible or visible alarm signals
B65B 61/26 - Auxiliary devices, not otherwise provided for, for operating on sheets, blanks, webs, binding material, containers or packages for marking or coding completed packages
B65G 54/02 - Non-mechanical conveyors not otherwise provided for electrostatic, electric, or magnetic
Provided herein are T-cell receptors (TCRs) that when expressed recombinantly on the surface of a T cell are able to recognize the DCAF4L2-derived peptide ILQDGQFLV (SEQ TD NO:1) when presented by HLA-A*02:01 sufficiently to activate the recombinant T cell. Importantly, exemplary TCRs provided herein were thoroughly screened for lack of cross-reactivity with similar peptides that may be presented by normal cells or tissue and for alloreactivity.
The present invention provides devices and methods for establishing aseptic connections between two or more components or subassemblies. The devices may be used in medical devices such as drug delivery pumps (10). In some embodiments, a connection is made between a drug container (50, 1050, 2050) and a fluid pathway connection assembly (300, 1300, 2300). The fluid pathway connection assembly may include a connection hub (312, 1312, 2312), a piercing member (316, 1316, 2316), and a piercing member retainer (314, 1314, 2314). The assembly may further include a first film (318, 1318, 2318) covering a cavity (312A, 1312A, 2312A), thereby maintaining the aseptic condition of the cavity. The drug container may hold a fluid drug and include a pierceable seal (326, 1326, 2326). A second film (322, 1322, 2322) may cover a recess (328, 1328, 2328) formed by the seal and thereby maintain the aseptic condition of the interior of the chamber. The piercing member may be caused to pierce the first and second film and the pierceable seal to open a fluid pathway for delivery of the fluid drug through the fluid pathway connection assembly.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides
C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
B01D 15/16 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
B01D 15/20 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
C07K 1/16 - ExtractionSeparationPurification by chromatography
C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum
56.
SYSTEMS, METHODS, AND USER INTERFACES FOR PROVIDING A FORM MAP
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/50 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
59.
VECTORS INCORPORATING A COMBINATION OF PROMOTERS DRIVING SELECTABLE MARKER EXPRESSION
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/48 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for varying, regulating, indicating or limiting injection pressure
G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine
61.
METHODS OF BUFFER PREPARATION FOR A THERAPEUTIC PROTEIN FORMULATION
G06Q 10/0639 - Performance analysis of employeesPerformance analysis of enterprise or organisation operations
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 70/40 - ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
66.
METHODS AND SYSTEMS FOR DETERMINING AN IMPACT OF ATTRIBUTES
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
67.
METHODS FOR CHROMATOGRAPHY AND CHROMATOGRAPHY MEDIUM REUSE
B01D 15/20 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
B01D 15/42 - Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
B01J 20/30 - Processes for preparing, regenerating or reactivating
C07K 1/16 - ExtractionSeparationPurification by chromatography
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
73.
5,6-FUSED BICYCLIC AMIDES AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS
A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
75.
5,6-FUSED AND 6,6-FUSED BICYCLIC ALCOHOLS AND ETHERS AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS
A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
76.
CONFIGURABLE HANDHELD BIOLOGICAL ANALYZERS FOR IDENTIFICATION OF BIOLOGICAL PRODUCTS BASED ON RAMAN SPECTROSCOPY USING ARTIFICIAL INTELLIGENCE
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/04 - Antineoplastic agents specific for metastasis
80.
METHOD OF USING AN ULTRASONIC FLOW SENSOR TO MONITOR FILL WEIGHT ACCURACY OF CLINICAL, COMMERCIAL, AND PROCESS DEVELOPMENT FILL/FINISH OPERATIONS
B65B 3/30 - Methods or devices for controlling the quantity of the material fed or filled by volumetric measurement
G01F 1/58 - Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow by using electric or magnetic effects by electromagnetic flowmeters
G01F 1/66 - Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow by measuring frequency, phase shift or propagation time of electromagnetic or other waves, e.g. using ultrasonic flowmeters
G01F 1/7086 - Measuring the time taken to traverse a fixed distance using optical detecting arrangements
G01F 3/20 - Measuring the volume flow of fluids or fluent solid material wherein the fluid passes through the meter in successive and more or less isolated quantities, the meter being driven by the flow with measuring chambers which expand or contract during measurement having flexible movable walls, e.g. diaphragms, bellows
G01F 11/12 - Apparatus requiring external operation adapted at each repeated and identical operation to measure and separate a predetermined volume of fluid or fluent solid material from a supply or container, without regard to weight, and to deliver it with measuring chambers moved during operation of the valve type, i.e. the separating being effected by fluid-tight or powder-tight movements
G01F 15/075 - Integration to give total flow, e.g. using mechanically-operated integrating mechanism using electrically-operated integrating means
G01F 23/20 - Indicating or measuring liquid level or level of fluent solid material, e.g. indicating in terms of volume or indicating by means of an alarm by measurement of weight, e.g. to determine the level of stored liquefied gas
G01F 25/10 - Testing or calibration of apparatus for measuring volume, volume flow or liquid level or for metering by volume of flowmeters
81.
SYSTEMS AND METHODS FOR MEASURING GEOMETRIC DIMENSIONS OF A SYRINGE AND/OR A PLUNGER STOPPER
G01B 11/02 - Measuring arrangements characterised by the use of optical techniques for measuring length, width, or thickness
G01B 21/04 - Measuring arrangements or details thereof, where the measuring technique is not covered by the other groups of this subclass, unspecified or not relevant for measuring length, width, or thickness by measuring coordinates of points
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
C12M 1/36 - Apparatus for enzymology or microbiology including condition or time responsive control, e.g. automatically controlled fermentors
C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
84.
VIRUS FILTRATION OPERATIONS EMPLOYING AN OVERSIZED VIRUS PREFILTER
A61K 9/19 - Particulate form, e.g. powders lyophilised
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
F26B 5/06 - Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
F26B 25/22 - Controlling the drying process in dependence on liquid content of solid materials or objects
87.
FIXED-POSITION IMAGING SYSTEMS FOR AUTOMATED VISUAL INSPECTION
G01B 11/02 - Measuring arrangements characterised by the use of optical techniques for measuring length, width, or thickness
G01B 11/26 - Measuring arrangements characterised by the use of optical techniques for measuring angles or tapersMeasuring arrangements characterised by the use of optical techniques for testing the alignment of axes
G01N 21/90 - Investigating the presence of flaws, defects or contamination in a container or its contents
88.
PROCESS FOR SYNTHESIZING NAPHTHYRIDINE DERIVATIVES AND INTERMEDIATES THEREOF
C07D 491/147 - Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
95.
RNAI CONSTRUCTS FOR INHIBITING TTR EXPRESSION AND METHODS OF USE THEREOF
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Disclosed herein are various solid forms of Compound A, including crystalline and amorphous forms of Compound A free base, as well as salt forms, cocrystals, and solvates thereof. Also disclosed are methods of making the salt, cocrystal, and solvate forms, and methods of treating diseases and disorders with the salt, cocrystal, and solvate forms (Compound A).
A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/529 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
patents
